Literature DB >> 34324160

Characterisation of the Mouse Cerebellar Proteome in the GFAP-IL6 Model of Chronic Neuroinflammation.

Rustam Asgarov1, Monokesh K Sen2, Meena Mikhael3, Tim Karl4,5,6, Erika Gyengesi1, David A Mahns7, Chandra S Malladi2, Gerald W Münch8.   

Abstract

GFAP-IL6 transgenic mice are characterised by astroglial and microglial activation predominantly in the cerebellum, hallmarks of many neuroinflammatory conditions. However, information available regarding the proteome profile associated with IL-6 overexpression in the mouse brain is limited. This study investigated the cerebellum proteome using a top-down proteomics approach using 2-dimensional gel electrophoresis followed by liquid chromatography-coupled tandem mass spectrometry and correlated these data with motor deficits using the elevated beam walking and accelerod tests. In a detailed proteomic analysis, a total of 67 differentially expressed proteoforms including 47 cytosolic and 20 membrane-bound proteoforms were identified. Bioinformatics and literature mining analyses revealed that these proteins were associated with three distinct classes: metabolic and neurodegenerative processes as well as protein aggregation. The GFAP-IL6 mice exhibited impaired motor skills in the elevated beam walking test measured by their average scores of 'number of footslips' and 'time to traverse' values. Correlation of the proteoforms' expression levels with the motor test scores showed a significant positive correlation to peroxiredoxin-6 and negative correlation to alpha-internexin and mitochondrial cristae subunit Mic19. These findings suggest that the observed changes in the proteoform levels caused by IL-6 overexpression might contribute to the motor function deficits.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Bioinformatics; Chronic inflammation; Metabolic dysregulation; Motor function; Neurodegeneration; Protein aggregation; Top-down proteomics

Mesh:

Substances:

Year:  2021        PMID: 34324160     DOI: 10.1007/s12311-021-01303-1

Source DB:  PubMed          Journal:  Cerebellum        ISSN: 1473-4222            Impact factor:   3.847


  77 in total

1.  CNS inflammation and neurodegeneration.

Authors:  Tanuja Chitnis; Howard L Weiner
Journal:  J Clin Invest       Date:  2017-09-05       Impact factor: 14.808

2.  Purkinje neuron physiology is altered by the inflammatory factor interleukin-6.

Authors:  Donna L Gruol; Thomas E Nelson
Journal:  Cerebellum       Date:  2005       Impact factor: 3.847

3.  In search of an anti-inflammatory drug for Alzheimer disease.

Authors:  Erika Gyengesi; Gerald Münch
Journal:  Nat Rev Neurol       Date:  2020-03       Impact factor: 42.937

4.  Interleukin-6-associated inflammatory processes in Alzheimer's disease: new therapeutic options.

Authors:  M Hüll; B L Fiebich; K Lieb; S Strauss; S S Berger; B Volk; J Bauer
Journal:  Neurobiol Aging       Date:  1996 Sep-Oct       Impact factor: 4.673

5.  Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway.

Authors:  Rodrigo A Quintanilla; Daniel I Orellana; Christian González-Billault; Ricardo B Maccioni
Journal:  Exp Cell Res       Date:  2004-04-15       Impact factor: 3.905

Review 6.  Neuroinflammation: the devil is in the details.

Authors:  Damon J DiSabato; Ning Quan; Jonathan P Godbout
Journal:  J Neurochem       Date:  2016-05-04       Impact factor: 5.372

7.  Interleukin-6 in the aging brain.

Authors:  J P Godbout; R W Johnson
Journal:  J Neuroimmunol       Date:  2004-02       Impact factor: 3.478

8.  Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients.

Authors:  M Huell; S Strauss; B Volk; M Berger; J Bauer
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

9.  Inflammation and neurodegeneration: chronicity matters.

Authors:  Keenan A Walker
Journal:  Aging (Albany NY)       Date:  2018-12-16       Impact factor: 5.682

10.  Chronic Microglial Activation in the GFAP-IL6 Mouse Contributes to Age-Dependent Cerebellar Volume Loss and Impairment in Motor Function.

Authors:  Erika Gyengesi; Alejandra Rangel; Faheem Ullah; Huazheng Liang; Garry Niedermayer; Rustam Asgarov; Madhuri Venigalla; Dhanushka Gunawardena; Tim Karl; Gerald Münch
Journal:  Front Neurosci       Date:  2019-04-03       Impact factor: 4.677

View more
  2 in total

1.  Histological and Top-Down Proteomic Analyses of the Visual Pathway in the Cuprizone Demyelination Model.

Authors:  Mohammed S M Almuslehi; Monokesh K Sen; Peter J Shortland; David A Mahns; Jens R Coorssen
Journal:  J Mol Neurosci       Date:  2022-05-30       Impact factor: 2.866

Review 2.  The roles of microglia and astrocytes in phagocytosis and myelination: Insights from the cuprizone model of multiple sclerosis.

Authors:  Monokesh K Sen; David A Mahns; Jens R Coorssen; Peter J Shortland
Journal:  Glia       Date:  2022-02-02       Impact factor: 8.073

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.